small molecule

LUXIQ

BETAMETHASONE VALERATE

Loss of exclusivity—loss of exclusivity
CompanyQUAGEN PHARMACEUTICALS LLC

Drug detail

Brand nameLUXIQ
Active ingredientBETAMETHASONE VALERATE
Strength0.12% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formAEROSOL, FOAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalFebruary 1999
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.